[Is interleukin-2 a break-through in the immunologic treatment of cancer?].
Lenner
P
P
Samtliga onkologiska kliniken, Regionsjukhuset, Umeå.
Henriksson
R
R
Bengtsson
N O
NO
D004341:Drug Evaluation; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D013601:T-Lymphocytes / Q000276:immunology
D007376:Interleukin-2
Interleukin-2-genombrott för immunologisk cancerbehandling?